Major generic drug companies, Teva Pharmaceuticals and Glenmark Pharmaceuticals, will pay a quarter-billion dollars to settle price-fixing charges and divest a key drug. This resolution is a significant step in fighting illegal practices and ensuring fair competition and affordable healthcare.